Summary

Market Size & Trends

The U.S. hormone therapy (retail side) market size was estimated at USD 11.63 billion in 2024 and is projected to reach USD 19.22 billion by 2033, growing at a CAGR of 5.83% from 2025 to 2033. This growth is driven by an increasing aging population and rising hormonal disorder prevalence. In addition, advances in delivery technologies, including oral pills, transdermal patches, subcutaneous pellets, and injectables, have enhanced efficacy, convenience, and adherence.

Moreover, the pharmacies now offer convenient dispensing and counseling, and platforms such as Ro, Noom, and Midi Health bundle telemedicine, online prescribing, and at-home delivery of hormones, with some combining GLP‑1 weight-loss treatments, driving sales upward.

U.S. Hormone Therapy (Retail Side) Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. hormone therapy (retail side) market report based on product, indication, route of administration, and distribution channel:
• Product Outlook (Revenue, USD Billion, 2021 - 2033)
• Sex Hormones
o Estrogen Replacement Therapy (ERT)
o Testosterone Replacement Therapy (TRT)
o Progesterone Therapy
o Combined Hormone Therapy
• Thyroid Hormones
• Growth Hormones
• Adrenal Hormones
• Other Hormones
• Indication Outlook (Revenue, USD Billion, 2021 - 2033)
• Menopause & Andropause Management
• Hypothyroidism
• Hypogonadism
• Growth Hormone Deficiency
• Gender Affirming Therapy
• Fertility Treatment
• Cosmetic Applications
• Other Indications
• Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
• Oral
• Parenteral
• Transdermal
• Other Route of Administration
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Offline Retail Pharmacies
o Large chains
o Independent pharmacies
• Online Pharmacies / Telehealth
o Pure-play online pharmacies
o Telehealth & subscription-based DTC brands
• Others (Specialized Hormone Clinics)

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.4.5. Details of Primary Research
1.4.6. Research Assumption
1.5. Information or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Data Visualization
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. Objectives
1.8.1. Objective - 1
1.8.2. Objective - 2
1.8.3. Objective - 3
1.9. List of Secondary Sources
1.10. List of Secondary Sources
Chapter 2. Executive Summary
2.1. U.S. Hormone Therapy (Retail Side) Market
2.1.1. Market Snapshot
2.1.2. Segment Snapshot
2.1.2.1. Product & indication segment outlook
2.1.2.2. Route of administration & distribution channel segment outlook
2.1.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Trends and Outlook
3.3. Market Dynamics
3.3.1. Market Driver Analysis
3.3.2. Market Restraint Analysis
3.4. Regulatory Framework
3.5. Business Environment Analysis Tools
3.5.1. Industry Analysis - Porter’s Five Forces Analysis
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrants
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.6. Pricing Analysis in Online vs. Offline Channels
3.7. Consumer Awareness Trends for Hormone Therapy
3.8. Direct-to-Consumer (DTC) Business Models Impact
Chapter 4. Product Business Analysis
4.1. U.S. Hormone Therapy (Retail Side) Market: Product Movement Analysis
4.2. U.S. Hormone Therapy (Retail Side) Market: Product Segment Dashboard
4.3. Product Movement & Market Share Analysis, 2024 & 2033
4.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Product
4.5. Sex Hormones
4.5.1. Sex Hormones Market, 2021 - 2033 (USD Million)
4.5.2. Estrogen Replacement Therapy (ERT)
4.5.2.1. Estrogen Replacement Therapy (ERT) market, 2021 - 2033 (USD Million)
4.5.3. Testosterone Replacement Therapy (TRT)
4.5.3.1. Testosterone Replacement Therapy (TRT) market, 2021 - 2033 (USD Million)
4.5.4. Progesterone Therapy
4.5.4.1. Progesterone therapy market, 2021 - 2033 (USD Million)
4.5.5. Combined Hormone Therapy
4.5.5.1. Combined hormone therapy market, 2021 - 2033 (USD Million)
4.6. Thyroid Hormones
4.6.1. Thyroid Hormones Market, 2021 - 2033 (USD Million)
4.7. Growth Hormones
4.7.1. Growth Hormones Market, 2021 - 2033 (USD Million)
4.8. Adrenal Hormones
4.8.1. Adrenal Hormones Market, 2021 - 2033 (USD Million)
4.9. Other Hormones
4.9.1. Other Hormones Market, 2021 - 2033 (USD Million)
Chapter 5. Indication Business Analysis
5.1. U.S. Hormone Therapy (Retail Side) Market: Indication Movement Analysis
5.2. U.S. Hormone Therapy (Retail Side) Market: Indication Segment Dashboard
5.3. Indication Movement & Market Share Analysis, 2024 & 2033
5.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Indication
5.5. Menopause & Andropause Management
5.5.1. Menopause & Andropause Management Market, 2021 - 2033 (USD Million)
5.6. Hypothyroidism
5.6.1. Hypothyroidism Market, 2021 - 2033 (USD Million)
5.7. Hypogonadism
5.7.1. Hypogonadism Market, 2021 - 2033 (USD Million)
5.8. Growth Hormone Deficiency
5.8.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
5.9. Gender Affirming Therapy
5.9.1. Gender Affirming Therapy Market, 2021 - 2033 (USD Million)
5.10. Fertility Treatment
5.10.1. Fertility Treatment Market, 2021 - 2033 (USD Million)
5.11. Cosmetic Applications
5.11.1. Cosmetic Applications Market, 2021 - 2033 (USD Million)
5.12. Other Indications
5.12.1. Other Indications Market, 2021 - 2033 (USD Million)
Chapter 6. Route of Administration Business Analysis
6.1. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Movement Analysis
6.2. U.S. Hormone Therapy (Retail Side) Market: Route of Administration Segment Dashboard
6.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
6.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Route of Administration
6.5. Oral
6.5.1. Oral Market, 2021 - 2033 (USD Million)
6.6. Parenteral
6.6.1. Parenteral Market, 2021 - 2033 (USD Million)
6.7. Transdermal
6.7.1. Transdermal Market, 2021 - 2033 (USD Million)
6.8. Other Route of Administration
6.8.1. Other Route of Administration Market, 2021 - 2033 (USD Million)
Chapter 7. Distribution Channel Business Analysis
7.1. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Movement Analysis
7.2. U.S. Hormone Therapy (Retail Side) Market: Distribution Channel Segment Dashboard
7.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
7.4. U.S. Hormone Therapy (Retail Side) Market Estimates & Forecast, by Distribution Channel
7.5. Offline Retail Pharmacies
7.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
7.5.2. Large Chains
7.5.2.1. Large chains market, 2021 - 2033 (USD Million)
7.5.3. Independent Pharmacies
7.5.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
7.6. Online Pharmacies / Telehealth
7.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
7.6.2. Pure-Play Online Pharmacies
7.6.2.1. Pure-play online pharmacies market, 2021 - 2033 (USD Million)
7.6.3. Independent Pharmacies
7.6.3.1. Independent pharmacies market, 2021 - 2033 (USD Million)
7.7. Telehealth & subscription-based DTC brands
7.7.1. Telehealth & subscription-based DTC brands Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company Categorization (Offline Pharmacies)
8.2. Company Categorization (Online Pharmacies)
8.3. Company Categorization (Specialized Hormone Clinics)
8.4. Participant’s Overview
8.4.1. Offline Pharmacies
8.4.2. Online Pharmacies
8.4.3. Specialized Hormone Clinics
8.5. Company Market Position Analysis
8.6. Strategy Mapping
8.6.1. Regional Expansion
8.6.2. Mergers & Acquisitions
8.6.3. Others
8.7. Company Profiles/Listing
8.8. Offline Pharmacies
8.8.1. CVS Health
8.8.1.1. Overview
8.8.1.2. Financial performance
8.8.1.3. Product benchmarking
8.8.1.4. Strategic initiatives
8.8.2. Walgreens Boots Alliance, Inc.
8.8.2.1. Overview
8.8.2.2. Financial performance
8.8.2.3. Product benchmarking
8.8.2.4. Strategic initiatives
8.8.3. Walmart Pharmacy
8.8.3.1. Overview
8.8.3.2. Financial performance
8.8.3.3. Product benchmarking
8.8.3.4. Strategic initiatives
8.8.4. Rite Aid Corp
8.8.4.1. Overview
8.8.4.2. Financial performance
8.8.4.3. Product benchmarking
8.8.4.4. Strategic initiatives
8.8.5. The Kroger Co.
8.8.5.1. Overview
8.8.5.2. Financial performance
8.8.5.3. Product benchmarking
8.8.5.4. Strategic initiatives
8.8.6. Albertsons
8.8.6.1. Overview
8.8.6.2. Financial performance
8.8.6.3. Product benchmarking
8.8.6.4. Strategic initiatives
8.8.7. Publix
8.8.7.1. Overview
8.8.7.2. Financial performance
8.8.7.3. Product benchmarking
8.8.7.4. Strategic initiatives
8.8.8. Costco Wholesale Corporation
8.8.8.1. Overview
8.8.8.2. Financial performance
8.8.8.3. Product benchmarking
8.8.8.4. Strategic initiatives
8.8.9. Meijer, Inc.
8.8.9.1. Overview
8.8.9.2. Financial performance
8.8.9.3. Product benchmarking
8.8.9.4. Strategic initiatives
8.9. Online Pharmacies
8.10. Hims & Hers Health, Inc
8.10.1. CVS Health
8.10.1.1. Overview
8.10.1.2. Financial performance
8.10.1.3. Product benchmarking
8.10.1.4. Strategic initiatives
8.10.2. Ro (Roman Health Ventures Inc.)
8.10.2.1. Overview
8.10.2.2. Financial performance
8.10.2.3. Product benchmarking
8.10.2.4. Strategic initiatives
8.10.3. Lemonaid Health, Inc.
8.10.3.1. Overview
8.10.3.2. Financial performance
8.10.3.3. Product benchmarking
8.10.3.4. Strategic initiatives
8.10.4. Mark Cuban Cost Plus Drug Company, PBC
8.10.4.1. Overview
8.10.4.2. Financial performance
8.10.4.3. Product benchmarking
8.10.4.4. Strategic initiatives
8.10.5. Amazon.com, Inc.
8.10.5.1. Overview
8.10.5.2. Financial performance
8.10.5.3. Product benchmarking
8.10.5.4. Strategic initiatives
8.10.6. Blink Health Administration LLC, Inc.
8.10.6.1. Overview
8.10.6.2. Financial performance
8.10.6.3. Product benchmarking
8.10.6.4. Strategic initiatives
8.10.7. GoodRx, Inc
8.10.7.1. Overview
8.10.7.2. Financial performance
8.10.7.3. Product benchmarking
8.10.7.4. Strategic initiatives
8.10.8. Honeybee Health Inc.
8.10.8.1. Overview
8.10.8.2. Financial performance
8.10.8.3. Product benchmarking
8.10.8.4. Strategic initiatives
8.10.9. TruePill
8.10.9.1. Overview
8.10.9.2. Financial performance
8.10.9.3. Product benchmarking
8.10.9.4. Strategic initiatives
8.10.10. NURX Inc.
8.10.10.1. Overview
8.10.10.2. Financial performance
8.10.10.3. Product benchmarking
8.10.10.4. Strategic initiatives
8.10.11. AgelessRx
8.10.11.1. Overview
8.10.11.2. Financial performance
8.10.11.3. Product benchmarking
8.10.11.4. Strategic initiatives
8.11. Specialized Hormone Clinics
8.12. Hims & Hers Health, Inc
8.12.1. BodyLogicMD
8.12.1.1. Overview
8.12.1.2. Financial performance
8.12.1.3. Product benchmarking
8.12.1.4. Strategic initiatives
8.12.2. Defy Medical
8.12.2.1. Overview
8.12.2.2. Financial performance
8.12.2.3. Product benchmarking
8.12.2.4. Strategic initiatives
8.12.3. Renew Vitality
8.12.3.1. Overview
8.12.3.2. Financial performance
8.12.3.3. Product benchmarking
8.12.3.4. Strategic initiatives
8.12.4. Victory Men’s Health
8.12.4.1. Overview
8.12.4.2. Financial performance
8.12.4.3. Product benchmarking
8.12.4.4. Strategic initiatives
8.12.5. Hone Health
8.12.5.1. Overview
8.12.5.2. Financial performance
8.12.5.3. Product benchmarking
8.12.5.4. Strategic initiatives
8.12.6. Joi & Blokes
8.12.6.1. Overview
8.12.6.2. Financial performance
8.12.6.3. Product benchmarking
8.12.6.4. Strategic initiatives
8.12.7. Ways2Well
8.12.7.1. Overview
8.12.7.2. Financial performance
8.12.7.3. Product benchmarking
8.12.7.4. Strategic initiatives
8.12.8. Honeybee Health Inc.
8.12.8.1. Overview
8.12.8.2. Financial performance
8.12.8.3. Product benchmarking
8.12.8.4. Strategic initiatives
8.12.9. 4Ever Young Anti-aging Solutions
8.12.9.1. Overview
8.12.9.2. Financial performance
8.12.9.3. Product benchmarking
8.12.9.4. Strategic initiatives
8.12.10. T CLINICS USA
8.12.10.1. Overview
8.12.10.2. Financial performance
8.12.10.3. Product benchmarking
8.12.10.4. Strategic initiatives